Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia and multiple sclerosis.[8] In chronic lymphocytic leukemia, it has been used as both a first line and second line treatment.[8] It is given by injection into a vein.[8]
It is a monoclonal antibody that binds to CD52, a protein present on the surface of mature lymphocytes, but not on the stem cells from which these lymphocytes are derived. After treatment with alemtuzumab, these CD52-bearing lymphocytes are targeted for destruction.
Alemtuzumab was approved for medical use in the United States in 2001.[8] (Mab)Campath was withdrawn from the markets in the US and the EU in 2012, to prepare for a higher-priced relaunch of Lemtrada aimed at multiple sclerosis.[9]
^"Alemtuzumab Use During Pregnancy". Drugs.com. 22 August 2022. Retrieved 6 January 2024.
^"TGA eBS - Product and Consumer Medicine Information Licence".
^"TGA eBS - Product and Consumer Medicine Information Licence".
^"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
^"Campath- alemtuzumab injection". DailyMed. 3 May 2023. Retrieved 6 January 2024.
^"Lemtrada- alemtuzumab injection, solution, concentrate". DailyMed. 23 May 2023. Retrieved 6 January 2024.
^"Lemtrada EPAR". European Medicines Agency. 12 September 2013. Retrieved 6 January 2024.
^ abcd"Alemtuzumab Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 15 July 2019.
^Cite error: The named reference pt was invoked but never defined (see the help page).
Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia and multiple sclerosis...
tumor cell. Examples include rituximab, ofatumumab, elotuzumab, and alemtuzumab. Antibodies under development have altered Fc regions that have higher...
associated with certain types of lymphoma. It is the protein targeted by alemtuzumab, a monoclonal antibody used for the treatment of chronic lymphocytic...
Design Labs, Inc. in Mountain View, California, in the 1980s and 1990s. Alemtuzumab is an early example of an antibody whose humanization did not include...
proteins with its Fc region. MAbs approved by the FDA for cancer include: Alemtuzumab Bevacizumab Cetuximab Dostarlimab Gemtuzumab ozogamicin Ipilimumab Nivolumab...
measures. There is high confidence that natalizumab, cladribine, or alemtuzumab are decreasing relapses over a period of two years for people with RRMS...
Initially, Slavin pioneered the use of monoclonal antibodies anti-CD52 (Alemtuzumab, now approved by FDA as Lemtrada) for prevention of graft-vs-host disease...
now owned by Mylan. Cablivi (Caplacizumab), for thrombosis. Campath (Alemtuzumab), for multiple sclerosis. Clolar (Clofarabine), for leukemia. Eloctate...
usually lethal, but it has been found to be responsive to Mitoxantrone and Alemtuzumab, and it has also been responsive to autologous stem cell transplantation...
more invasive and for it even less data is available. Immunoadsorption Alemtuzumab The histaminergic neurons have a very important role in preserving consciousness...
Cassiopeiae UH-1H, a type of Bell UH-1 Iroquois Campath-1H, a brand of Alemtuzumab Ardiden 1H, a model of HAL/Turbomeca Shakti Blendkörper 1H, smoke grenade...
interferons beta-1a and beta-1b; monoclonal antibodies: natalizumab, alemtuzumab, ocrelizumab, ofatumumab, and ublituximab; and immunomodulators: glatiramer...
(also known as ErbB2) receptor expressed in some types of breast cancer Alemtuzumab Cetuximab target the epidermal growth factor receptor (EGFR). It is approved...
responsive. There are also anecdotal reports against using fingolimod or alemtuzumab. Residual disability develops in 50–80% of patients, with transverse...
cells were engineered to attack the leukemia cells, to be resistant to Alemtuzumab, and to evade detection by the host immune system after introduction...
used to treat MS—such as interferon-β, fingolimod, natalizumab, and alemtuzumab—worsen NMO disease progression and should not be used to treat NMO. Normally...
suppress the immune system to prevent rejection of organ transplants; alemtuzumab, which is anti-CD52 and used to treat blood cancers as well as multiple...
effectively treat PM, and there is no proven effective therapy for IBM. Alemtuzumab is being studied but as of May 2013 it had not demonstrated clinical...
antibodies against CD20 (rituximab, ofatumumab and obinutuzumab) and CD52 (alemtuzumab). Notably, some of the effects of the targeted therapies such as BCR...
Global Information
(what is this?) (verify)